AlphAIAlphAI — Financial news for AI agents
stocktitan.netNOV 22 min read$ABT

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

Original reporting
stocktitan.net
Published Nov 2, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABT
Bullish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

First-year closure rates >98% and low complication rates suggest strong product performance.

02

Market read

Positive pivotal trial data for a large‑cap med‑tech device could lift Abbott's stock and affect the broader cardiac device sector.

03

What to watch

Regulatory approval timeline and insurance coverage decisions could limit upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott announced investigational Amulet 360 LAA occluder results at TCT conference; device aims to reduce stroke risk in non‑valvular AFib patients.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott released first-year VERITAS study results showing >98% stroke-free rate for its Amulet 360 LAA occluder.

Expected impact

likely upside as investors price in favorable clinical outcomes.

Evidence & confidence

First disclosure of pivotal study results for a large‑cap medical device; positive efficacy signals typically lift stock.

Market effects

Sector

May increase confidence in LAA occlusion market and benefit competing device makers.

Regional

U.S. healthcare device sector could see modest lift.

Global

Positive data may influence global adoption of LAA closure therapies.

Counterpoint

What could challenge this read

If reimbursement or adoption hurdles persist, the data may not translate to sales.

Key entities

  • Company
    Abbott Laboratories

    US‑listed medical device maker (NYSE: ABT).

  • Product
    Amulet 360 LAA Occluder

    Investigational left atrial appendage closure device.

Read at source← All news

StoryAbbott reports favorable one-year results for investigational Amulet 360 device

Also covered by

2 outlets

Related articles

NOV 2
$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com2 min
NOV 2
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com2 min
NOV 1
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net2 min
NOV 1
$ABTMedAI 9/10

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

prnewswire.com2 min
OCT 31
$AVGOMed

Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks

Analysts made notable calls this week. D.A. Davidson upgraded Broadcom (AVGO) to Buy with a $400 price target, citing AI-related growth prospects. William Blair downgraded Moderna (MRNA) to Market Perform due to valuation concerns. Argus downgraded Abbott (ABT) to Hold after its reduced growth outlook. Jefferies upgraded Rivian (RIVN) to Buy, citing progress in margins and execution. GF Securities raised AMD's (AMD) price target to $720, expecting strong data center growth.

tradingview.com2 min